The role of vitamin K in the prognosis of patients with hepatocellular carcinoma: a systematic review and meta-analysis.
메타분석
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
688 subjects were incorporated.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Future investigations should optimize VK dosing and administration strategies and explore its potential synergy with immunotherapy. [SYSTEMATIC REVIEW REGISTRATION] https://www.crd.york.ac.uk/PROSPERO/view/CRD420251106693, identifier CRD420251106693.
[OBJECTIVE] This meta-analysis aimed to evaluate the influence of vitamin K (VK) as an adjunctive therapy on the prognosis of patients with hepatocellular carcinoma (HCC), with a specific focus on its
- 95% CI 0.58-1.01
- HR 0.77
- 연구 설계 meta-analysis
APA
Guo L, Wang Y, et al. (2026). The role of vitamin K in the prognosis of patients with hepatocellular carcinoma: a systematic review and meta-analysis.. Frontiers in oncology, 16, 1765445. https://doi.org/10.3389/fonc.2026.1765445
MLA
Guo L, et al.. "The role of vitamin K in the prognosis of patients with hepatocellular carcinoma: a systematic review and meta-analysis.." Frontiers in oncology, vol. 16, 2026, pp. 1765445.
PMID
41930200 ↗
Abstract 한글 요약
[OBJECTIVE] This meta-analysis aimed to evaluate the influence of vitamin K (VK) as an adjunctive therapy on the prognosis of patients with hepatocellular carcinoma (HCC), with a specific focus on its clinical value in non-resected individuals.
[METHODS] We systematically retrieved Chinese and English databases, including PubMed and Embase, to select randomized controlled trials (RCTs) and cohort studies comparing VK combined with standard therapy versus standard therapy alone. Methodological quality was evaluated via the Newcastle-Ottawa Scale for cohort studies and the Cochrane Risk of Bias tool (RoB-2) for RCTs. The primary endpoints were overall survival (OS) and progression-free survival (PFS). The secondary endpoint was recurrence risk. Pooled hazard ratios (HRs) and relative risks (RRs) were computed by fixed- or random-effects models. Subgroup analyses (surgery vs. transarterial chemoembolization [TACE]) and time stratification (12-48M) were conducted to explore heterogeneity sources.
[RESULTS] Eleven studies involving 688 subjects were incorporated. The fixed-effects meta-analysis indicated that VK combined with standard therapy did not significantly improve OS (pooled HR = 0.77, 95% CI: 0.58-1.01). However, this combination prolonged PFS (pooled HR = 0.62, 95% CI: 0.47-0.82). Subgroup analysis based on PFS demonstrated more pronounced benefit in TACE-treated subjects (HR = 0.51, 95% CI: 0.34-0.77). Furthermore, VK combined with standard therapy reduced recurrence risk (pooled HR = 0.26, 95% CI: 0.15-0.46).
[CONCLUSION] Adjunctive VK improves PFS and reduces recurrence risk in HCC subjects, demonstrating particular benefit for those with unresectable tumors receiving TACE. No significant OS advantage was observed. Future investigations should optimize VK dosing and administration strategies and explore its potential synergy with immunotherapy.
[SYSTEMATIC REVIEW REGISTRATION] https://www.crd.york.ac.uk/PROSPERO/view/CRD420251106693, identifier CRD420251106693.
[METHODS] We systematically retrieved Chinese and English databases, including PubMed and Embase, to select randomized controlled trials (RCTs) and cohort studies comparing VK combined with standard therapy versus standard therapy alone. Methodological quality was evaluated via the Newcastle-Ottawa Scale for cohort studies and the Cochrane Risk of Bias tool (RoB-2) for RCTs. The primary endpoints were overall survival (OS) and progression-free survival (PFS). The secondary endpoint was recurrence risk. Pooled hazard ratios (HRs) and relative risks (RRs) were computed by fixed- or random-effects models. Subgroup analyses (surgery vs. transarterial chemoembolization [TACE]) and time stratification (12-48M) were conducted to explore heterogeneity sources.
[RESULTS] Eleven studies involving 688 subjects were incorporated. The fixed-effects meta-analysis indicated that VK combined with standard therapy did not significantly improve OS (pooled HR = 0.77, 95% CI: 0.58-1.01). However, this combination prolonged PFS (pooled HR = 0.62, 95% CI: 0.47-0.82). Subgroup analysis based on PFS demonstrated more pronounced benefit in TACE-treated subjects (HR = 0.51, 95% CI: 0.34-0.77). Furthermore, VK combined with standard therapy reduced recurrence risk (pooled HR = 0.26, 95% CI: 0.15-0.46).
[CONCLUSION] Adjunctive VK improves PFS and reduces recurrence risk in HCC subjects, demonstrating particular benefit for those with unresectable tumors receiving TACE. No significant OS advantage was observed. Future investigations should optimize VK dosing and administration strategies and explore its potential synergy with immunotherapy.
[SYSTEMATIC REVIEW REGISTRATION] https://www.crd.york.ac.uk/PROSPERO/view/CRD420251106693, identifier CRD420251106693.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Exploring molecular mechanisms of radioactive iodine therapy in thyroid cancer using single-cell RNA sequencing data.
- HMGB1: From Molecular Functions to Clinical Applications in Cancer and Inflammatory Diseases.
- Ponatinib confers adult human cardiomyocyte toxicity via inhibition of AKT signaling.
- Clinical risk prediction in lung adenocarcinoma using MAL gene and tumor microenvironment features.
- Correction: Correlation analysis between RAS gene mutations and pathological morphological features in colorectal cancer.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Raman Spectroscopic Signatures of Hepatic Carcinoma: Progress and Future Prospect.
- Heat Shock Protein 47 as a Novel Predictive and Diagnostic Biomarker for Thrombosis in Hepatocellular Carcinoma.
- Crosstalk Between -Regulatory Elements and Metabolism Reprogramming in Hepatocellular Carcinoma.
- Enhanced efficacy and long-term survival with SBRT plus PD-1 inhibitors versus SBRT alone in unresectable HCC: a multicenter PSM study.
- Risks, Benefits, and Molecular Targets of Fenugreek Administration in the Treatment of Hepatocellular Carcinoma.
- Machine learning integrating MRI and clinical features predicts early recurrence of hepatocellular carcinoma after resection.